MTND2P21

Across TCGA pan-cancer cohorts, MTND2P21 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated MTND2P21 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTND2P21 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND2P21 expression acts as an unfavorable survival marker, although some lineages such as UCS and KICH show a favorable association.

MESO, UCS, and DLBC are the cancer types where MTND2P21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	II,III,IV	0.089	0.575	<.001	126	view →
UCS	OS	Tertile	III,IV	1.000	0.260	.004	126	view →
DLBC	OS	Tertile	All	0.053	0.936	<.001	72	view →
KICH	OS	Tertile	All	1.000	0.705	.003	63	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
BLCA	OS	Tertile	All	0.845	0.554	.042	12	view →
PRAD	OS	Tertile	All	0.970	0.997	.021	12	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	9	view →
READ	OS	Tertile	IV	0.659	0.939	.034	9	view →
LGG	OS	Tertile	All	0.805	0.928	.008	9	view →
STAD	DFS	Median	IV	0.565	0.170	.022	7	view →
ESCA	OS	Tertile	IV	0.238	0.597	.047	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

MTND2P21–MESO (OS)

Open the MESO breakdown →